Source comparison
Why the CJC-1295 DAC vs No DAC Distinction Exists
The original CJC-1295 peptide developed in the early 2000s included a Drug Affinity Complex (DAC) modification. A lysine-based linker molecule that binds to serum albumin in the bloodstream, extending the peptide's half-life from 30 minutes to approximately 6–
This comparison does not assign a generated winner or score.
- The original CJC-1295 peptide developed in the early 2000s included a Drug Affinity Complex (DAC) modification. A lysine-based linker molecule that binds to serum albumin in the bloodstream, extending the peptide's half-life from 30 minutes to approximately 6–8 days. This modification allows once-weekly dosing but creates a continuous elevation of growth hormone (GH) rather than mimicking the body's natural pulsatile release pattern. Natural GH secretion operates in distinct pulses. Primarily during deep sleep and post-exercise. With baseline levels dropping to near-zero between pulses. DAC-modified CJC-1295 eliminates this pulsatility, maintaining elevated GH levels continuously.
- Researchers seeking to preserve natural GH pulse dynamics began requesting the peptide without the DAC modification, leading suppliers to label the unmodified version 'CJC-1295 No DAC'. Which is molecularly identical to Mod GRF 1-29 (also called Modified GRF 1-29 or Sermorelin analog). Both names refer to the same 29-amino-acid GHRH analog with four amino acid substitutions compared to native GHRH. These substitutions increase resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) in plasma, extending the functional half-life from under 7 minutes (native GHRH) to approximately 30 minutes. This extension is long enough to reach the anterior pituitary and stimulate somatotroph cells but short enough to clear before the next natural GH pulse begins.
- The key practical difference: DAC-modified CJC-1295 is dosed once weekly; CJC-1295 No DAC / Mod GRF requires dosing 1–3 times daily to align with natural GH pulse windows. Continuous GH elevation from DAC variants may blunt pituitary sensitivity over time through receptor downregulation. A concern that doesn't apply to pulsatile protocols. From our experience working with research protocols in this space, the DAC vs No DAC choice fundamentally alters the pharmacokinetic profile and requires completely different timing strategies when paired with ipamorelin.